教師資料查詢 | 類別: 期刊論文 | 教師: 張玉坤 Yue-cune Chang (瀏覽個人網頁)

標題:Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
學年96
學期1
出版(發表)日期2008/01/01
作品名稱Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
作品名稱(其他語言)
著者Lane, Hsien-Yuan; Liu, Yi-Ching; Huang, Chieh-Liang; Chang, Yue-Cune; Liau, Chun-Hui; Perng, Cheng-Hwang; Tsai, Guochuan E.
單位淡江大學數學學系
出版者Philadelphia: Elsevier Inc.
著錄名稱、卷期、頁數Biological Psychiatry 63(1), pp.9–12
摘要Background
Small molecules that enhance the N-methyl-D-aspartate (NMDA) neurotransmission have been shown to be beneficial as adjuvant therapy for schizophrenia. Among these compounds, sarcosine (a glycine transporter-I inhibitor), when added to an existing regimen of antipsychotic drugs, has shown its efficacy for both chronically stable and acutely ill patients. However, the efficacy of these agents as a primary antipsychotic agent has not yet been demonstrated.

Methods
Twenty acutely symptomatic drug-free patients with schizophrenia were randomly assigned under double-blind conditions to receive a 6-week trial of 2 g or 1 g of sarcosine daily.

Results
Overall, patients in the 2-g group were more likely to respond as defined by a 20% or more reduction of the Positive and Negative Syndrome Scale total score, particularly among antipsychotic-naïve patients. However, there was no significant between-group difference in the sarcosine dose × time interaction analysis. Both doses were well tolerated with minimal side effects.

Conclusions
Although patients receiving the 2-g daily dose were more likely to respond, it requires further clarification whether the effect is limited to the antipsychotic-naive population. Future placebo- or active-controlled, larger-sized studies are needed to fully assess sarcosine’s effects.
關鍵字Glutamate; GlyT-1; N-methyl-D-aspartate; sarcosine; schizophrenia
語言英文
ISSN0006-3223
期刊性質國外
收錄於SCI
產學合作
通訊作者Tsai, Guochuan E.
審稿制度
國別美國
公開徵稿
出版型式紙本
相關連結
Google+ 推薦功能,讓全世界都能看到您的推薦!